Pill vs. infusion: new hope for rare neurological disease

NCT ID NCT05222906

Summary

This study is testing if a daily oral pill called venglustat can work as well as the current standard of care—biweekly intravenous infusions—for maintaining stability in people with Gaucher disease type 3. It involves about 43 adults and teenagers (12+) who are already stable on their current infusion therapy. The main goal is to see if the pill can keep their neurological and physical symptoms from getting worse over a year.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GAUCHER'S DISEASE TYPE III are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • 47-87, boulevard de l'hôpital - Investigational Site Number: 2500003

    Paris, 75013, France

  • Azienda Ospedaliera Universitaria (AOU) "Federico II" - Investigational Site Number: 3800002

    Naples, 80131, Italy

  • Children's Hospital Research Institute of Manitoba - Investigational Site Number: 1240001

    Winnipeg, Manitoba, R3E 3P4, Canada

  • Cukurova University Medical School Hospital-Investigational Site Number : 7920001

    Adana, 01790, Turkey (Türkiye)

  • Debreceni Egyetem, Klinikai Központ, Reumatológiai Klinika - Investigational Site Number: 3480001

    Debrecen, H-4032, Hungary

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Investigational Site Number : 3800003

    Milan, Lombardy, 20122, Italy

  • Gazi University Medical Hospital-Investigational Site Number : 7920002

    Ankara, 06500, Turkey (Türkiye)

  • Hopital Necker - Investigational Site Number: 2500001

    Paris, 75015, France

  • Hospital de Ninos - Investigational Site Number: 320001

    Buenos Aires, 1426, Argentina

  • Investigational Site Number : 8260001

    London, NW3-2PF, United Kingdom

  • Istanbul University Medical Faculty Hospital-Investigational Site Number : 7920004

    Istanbul, 34093, Turkey (Türkiye)

  • Lysosomal & Rare Disorders Research & Treatment Center, Inc - Investigational Site Number: 8400001

    Fairfax, Virginia, 22030, United States

  • National Taiwan University Hospital-Investigational Site Number: 1580001

    Taipei, Taiwan, 10041, China

  • Odawara Municipal Hospital-Investigational Site Number : 3920002

    Odawara, Kanagawa, 250-8558, Japan

  • Peking Union Medical College Hospital - Investigational Site Number: 1560001

    Beijing, 100005, China

  • SphinCS GmbH - Investigational Site Number: 2760001

    Hochheim am Main, 65239, Germany

  • Texas Oncology - Medical City Dallas Site Number : 8400008

    Dallas, Texas, 75230, United States

  • The First Affiliated Hospital - Investigational Site Number: 1560002

    Guangzhou, 510080, China

  • Tohoku University School of Medicine - Investigational Site Number: 3920001

    Sendai, 980-8574, Japan

  • University of Iowa - Investigational Site Number: 8400002

    Iowa City, Iowa, 52242, United States

  • Xinhua Hospital - Investigational Site Number: 1560004

    Shanghai, 200092, China

  • Yale University School of Medicine - Investigational Site Number: 8400003

    New Haven, Connecticut, 06511, United States

Conditions

Explore the condition pages connected to this study.